287 related articles for article (PubMed ID: 37046766)
1. Precision Oncology Targets in Biliary Tract Cancer.
Farha N; Dima D; Ullah F; Kamath S
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046766
[TBL] [Abstract][Full Text] [Related]
2. Current options and future directions of systemic therapy for advanced biliary tract cancer.
Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
[TBL] [Abstract][Full Text] [Related]
3. Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine.
Mie T; Sasaki T; Okamoto T; Furukawa T; Takeda T; Kasuga A; Ozaka M; Sasahira N
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473240
[TBL] [Abstract][Full Text] [Related]
4. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
[TBL] [Abstract][Full Text] [Related]
5. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
[TBL] [Abstract][Full Text] [Related]
6. Targets for therapy in biliary tract cancers: the new horizon of personalized medicine.
Iyer P; Chen MH; Goyal L; Denlinger CS
Chin Clin Oncol; 2020 Feb; 9(1):7. PubMed ID: 32146818
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
8. Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?
Gupta A; Kurzrock R; Adashek JJ
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900367
[TBL] [Abstract][Full Text] [Related]
9. A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
Aimar G; Paratore C; Zichi C; Marino D; Sperti E; Caglio A; Gamba T; De Vita F; Di Maio M
Explor Target Antitumor Ther; 2021; 2(5):448-464. PubMed ID: 36045702
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.
Chakrabarti S; Kamgar M; Mahipal A
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722188
[TBL] [Abstract][Full Text] [Related]
11. Treating Biliary Tract Cancers: New Targets and Therapies.
Ho J; Fiocco C; Spencer K
Drugs; 2022 Nov; 82(17):1629-1647. PubMed ID: 36441502
[TBL] [Abstract][Full Text] [Related]
12. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
13. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
Lamarca A; Barriuso J; McNamara MG; Valle JW
J Hepatol; 2020 Jul; 73(1):170-185. PubMed ID: 32171892
[TBL] [Abstract][Full Text] [Related]
14. Changing Landscape of Systemic Therapy in Biliary Tract Cancer.
Woods E; Le D; Jakka BK; Manne A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565266
[TBL] [Abstract][Full Text] [Related]
15. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options.
Personeni N; Lleo A; Pressiani T; Colapietro F; Openshaw MR; Stavraka C; Pouptsis A; Pinato DJ; Rimassa L
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33202975
[TBL] [Abstract][Full Text] [Related]
16. Cell of origin in biliary tract cancers and clinical implications.
Moeini A; Haber PK; Sia D
JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for the treatment of biliary tract cancer: an evolving landscape.
Wilbur HC; Azad NS
Ther Adv Med Oncol; 2024; 16():17588359241235799. PubMed ID: 38449562
[TBL] [Abstract][Full Text] [Related]
18. Current biologics for treatment of biliary tract cancers.
Zhao DY; Lim KH
J Gastrointest Oncol; 2017 Jun; 8(3):430-440. PubMed ID: 28736630
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging therapies for advanced biliary tract cancers.
Kam AE; Masood A; Shroff RT
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
[TBL] [Abstract][Full Text] [Related]
20. FGFR2 Inhibition in Cholangiocarcinoma.
Vogel A; Segatto O; Stenzinger A; Saborowski A
Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
